AGÕæÈ˹ٷ½

STOCK TITAN
  1. Home
  2. Sec-filings
  3. ESPR
  4. [144] Esperion Therapeutics, Inc. SEC Filing

[144] Esperion Therapeutics, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144
Rhea-AI Filing Summary
Analyzing...
Positive
  • None.
Negative
  • None.

Filing content is currently unavailable.

Source:

Stock ESPR logo
Esperion Therape

NASDAQ:ESPR

ESPR Rankings

#5314 Ranked by Market Cap
N/A Ranked by Dividends

ESPR Latest News

Aug 5, 2025
Esperion Reports Second Quarter 2025 Financial Results and Provides Business Update
Jul 22, 2025
Esperion to Report Second Quarter 2025 Financial Results on August 5
Jul 8, 2025
Esperion Reaches Settlement Agreement with Third ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) Prior to April 19, 2040
Jul 1, 2025
Esperion Appoints Craig Thompson to Board of Directors
Jun 2, 2025
Esperion Reaches Settlement Agreement with Second ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) Prior to April 19, 2040

ESPR Latest SEC Filings

Aug 5, 2025
[8-K] Esperion Therapeutics, Inc. Reports Material Event
Jul 18, 2025
[Form 4] Esperion Therapeutics, Inc. Insider Trading Activity
Jul 18, 2025
[Form 4] Esperion Therapeutics, Inc. Insider Trading Activity
Jul 17, 2025
[144] Esperion Therapeutics, Inc. SEC Filing
Jul 2, 2025
[Form 4] Esperion Therapeutics, Inc. Insider Trading Activity

ESPR Stock Data

321.08M
199.11M
0.57%
59.4%
11.15%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
United States
ANN ARBOR